The IRS specifically excludes expenses that are merely beneficial to general health from qualified medical expenses, and many HRA plan documents echo that language by excluding weight-loss medications taken without a documented medical condition
Conclusion GLP-1 receptor agonists have transformed obesity treatment by addressing the biological mechanisms that regulate hunger and weight
For compounded tirzepatide, the initial package is listed at $349/month (originally $259 per brand)
NICE guideline NG28 for type 2 diabetes and technology appraisals for weight management formulations emphasise the importance of patient education and individualised care when initiating GLP-1 therapy
Similar patterns were observed decades ago with bariatric, or weight loss, surgery
J., Doros, G., Hammerer, P